PAH News

March 21, 2019March 21, 2019

Resverlogix Obtains Funding for Phase 2 Trial Testing Apabetalone in PAH

News, PAH News

Resverlogix announced that it has received funding from the Canadian Institutes for Health Research for a Phase 2 clinical study investigating the safety and efficacy of its proprietary therapy apabetalone (RVX-208) ... Read more

March 20, 2019March 20, 2019

Opsumit Has Potential to Improve Right Ventricle Function in PAH Patients, Phase 4 Data Show

News, PAH News

Treatment with Opsumit (macitentan) can significantly improve the heart’s right ventricular function, reverse cardiac tissue remodeling, and reduce pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension (PAH), preliminary ... Read more

March 18, 2019March 18, 2019

Cell Therapies Show Potential as Treatment for PAH, Review Finds

News, PAH News

Regenerative cell therapy can induce significant improvements in key clinical features of pulmonary arterial hypertension (PAH) in animal models, a review study shows. The study’s findings suggest that such ... Read more

March 15, 2019March 22, 2019

Estrogen May Help Protect Against Heart Changes in PAH, Animal Study Suggests

News, PAH News

Estrogen, one of the major female sex hormones, has a protective effect in pulmonary arterial hypertension (PAH) by halting oxidative stress and collagen deposition, a rat study suggests. The ... Read more

March 14, 2019March 19, 2019

Liquidia’s LIQ861 Safe and Effective in PAH Patients, Phase 3 Trial Suggests

News, PAH News

A Phase 3 clinical trial testing LIQ861 met its primary objective, showing that the investigational inhaled dry powder treprostinil formulation is safe and effective for the treatment of pulmonary arterial hypertension (PAH), according ... Read more

March 11, 2019March 11, 2019

Study Reveals Possible Reason for Women’s Higher Risk of PAH

News, PAH News

Women’s pulmonary artery muscle cells produce more of a signal molecule called hypoxia-inducible factor 1-alpha (HIF1α), which may contribute to the higher prevalence of pulmonary arterial hypertension (PAH) in women compared ... Read more

March 6, 2019March 12, 2019

Transition from PDE5i to Adempas Without Washout Period Deemed Safe

CTEPH News, News, PAH News, PH News

Transition from phosphodiesterase-5 inhibitors (PDE5i) — such as United Therapeutics’ Adcirca (taladafil) and Pfizer‘s Revatio (sildenafil) — to Bayer‘s Adempas (riociguat), a soluble guanylate cyclase (sGC) stimulator, without a washout period ... Read more

February 22, 2019February 28, 2019

Complexa Starts Dosing in Phase 2 Trial to Evaluate CXA-10 for PAH

News, PAH News

The first patient has been given the investigational therapy CXA-10 in an ongoing Phase 2 trial in patients with pulmonary arterial hypertension (PAH), Complexa, the product’s developer, announced. The ... Read more

February 21, 2019February 27, 2019

Higher Levels of 2 Autoantibodies Could Help Diagnose CTEPH and PAH, Study Suggests

CTEPH News, News, PAH News

Patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) have higher serum levels of antibodies against the EDX2 and PHAX proteins, according to research which suggests ... Read more

February 18, 2019February 22, 2019

Approved Lung Cancer Therapy Dacomitinib Shows Promise in Treating PAH, Animal Study Finds

News, PAH News

Dacomitinib, a medicine recently approved by the U.S. Food and Drug Administration for the treatment of certain forms of lung cancer, showed promising therapeutic effects in two animal models ... Read more

Pin It on Pinterest